PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
The DOI matches its Crossref record.
Abstract
104 Background: Biomarkers of clinical benefit of immunotherapies, such as non-synonymous mutations, mutational load, PD-L1 IHC and immune signatures, have not been systematically evaluated in mUC patients (pts) treated with anti–PD-L1 agents. Methods: Exploratory analyses of immune and genetic predictors of response to atezo were performed on archival tumor specimens from mUC pts (NCT02108652 cohort 2). PD-L1 expression in tumor samples was assessed by IHC (SP142 assay) and associated with response as determined by RECIST v1.1 (central review). Gene expression was quantified by RNA-seq (Illumina TruSeq RNA Access; n = 195); molecular subtypes were assigned as per TCGA. Mutations were detected by genomic profiling (FoundationOne 315-cancer gene panel; n = 150) to estimate overall load. Results: PD-L1 tumor-infiltrating immune cell (IC) status was associated with CD8+ T effector (Teff) gene expression levels (P < 0.0001). Notably, response to atezo was associated with high expression of CXCL9 (P = 0.0057) and CXCL10 (P = 0.0079). Evaluable samples were classified into luminal (n = 73) and basal (n = 122) TCGA subtypes. PD-L1 IC prevalence was enriched in basal (60%) vs luminal (23%) samples (P < 0.0001); elevated tumor cell PD-L1 was mostly restricted to the basal subtype (39% basal vs 4% luminal, P < 0.0001) and did not correlate with ORR. Teff expression was elevated in luminal cluster II and basal III/IV and not in luminal I. Responses occurred in all subtypes, but ORR was significantly higher in luminal II samples: 34% (P = 0.0017). While median mutational load was significantly increased in responders (12.4/Mb) vs non-responders (6.4/Mb; P < 0.0001) and correlated with both PFS (P = 0.003) and OS (P = 0.014), these associations were independent of TCGA subtype. Conclusions: PD-L1 expression on IC was associated with response to atezo. Intrinsic TCGA subtype and mutational load each added predictive value. Simultaneous classification by these characteristics in mUC pts treated with atezo further defines the drivers of immune responsiveness and may suggest potential combination strategies. Clinical trial information: NCT02108652.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Self-citationTeo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544
“proval of two PD-L1 IHC companion diagnostics, multiple PD-L1 IHC assays have demonstrated conflicting data in mUC, and their clinical utility remains unproven.(2-6,9) MLwas previously shown to be associated with clinical benefit in mUC.”
MethodSelf-citation
Metadata
- Authors
- Rosenberg, J. E., Petrylak, D. P., Van Der Heijden, M. S., Necchi, A., O'Donnell, P. H., Loriot, Y., Retz, M., Perez-Gracia, J. L., Bellmunt, J., Grivas, P., Joseph, R. W., Fong, L., Kadel, E. E., Boyd, Z., Nickles, D., Frampton, G. M., Bourgon, R., Hegde, P. S., Mariathasan, S., & Powles, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-20
- Volume
- 34
- Issue
- 15_suppl
- Pages
- 104-104
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2625718262
- Cited by
- 44
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.104
- The paper
- Rosenberg, J. E., Petrylak, D. P., Van Der Heijden, M. S., Necchi, A., O'Donnell, P. H., Loriot, Y., Retz, M., Perez-Gracia, J. L., Bellmunt, J., Grivas, P., Joseph, R. W., Fong, L., Kadel, E. E., Boyd, Z., Nickles, D., Frampton, G. M., Bourgon, R., Hegde, P. S., Mariathasan, S., & Powles, T. (2016). PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.